A Randomized, Double-Blind, Placebo and Active-Control, Crossover Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists in Physically Dependent Opioid Users with Moderate-to-Severe Opioid Use Disorder
Assessing the Abuse Potential of Oxymorphone in Opioid Use Disorder Patients
Sponsor: Food and Drug Administration
Enrolling: Male and Female Patients
Study Length: 8 Weeks
Clinic Visits: 45
IRB Number: 7565
U.S. Govt. ID: NCT03205423
Contact: Vincent Woolfolk, MA: 646-774-6243 / surc@columbia.edu
Additional Study Information: This 8-week inpatient study seeks to recruit healthy male and female patients who are currently using heroin or non-medically using opioid analgesics. Following screening, participants are admitted onto the inpatient unit where they complete testing sessions throughout the inpatient stay. Participants are compensated for each screening visit and for each inpatient day if they enroll in the trial. Total payments will be approximately $6720.
This study is closed
Sandra Comer, PhD
Do You Qualify?
Are you between the ages of 21 to 55? Yes No
Do you use heroin? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Vincent Woolfolk, MA